u/nervgenerator

No, it’s unlikely to be exactly as effective, but it has strong potential to be meaningfully effective for stroke survivors as well—potentially in a comparable or complementary way. Here's a balanced, evidence-based view.

Core Mechanism (Why It Could Translate)NervGen’s lead candidate, NVG-291, is a peptide that mimics the intracellular "wedge" domain of the receptor PTPσ (protein tyrosine phosphatase sigma). It disrupts the inhibitory effects of chondroitin sulfate proteoglycans (CSPGs), which surge after CNS damage and form a glial scar that blocks:Axonal regeneration/sprouting

Neuroplasticity (new neural connections)

Remyelination

Migration of new neurons (neuroblasts)

This CSPG-PTPσ pathway is a conserved biological barrier across many forms of nervous system damage—not unique to spinal cord injury (SCI).

Evidence in SCIPositive Phase 1b/2a (CONNECT SCI) results in chronic cervical SCI (1–10 years post-injury): Statistically significant improvements in motor connectivity (e.g., ~3-fold increase in MEP amplitude to a key hand muscle), hand function (GRASSP scores), gait quality, bladder control, and patient-reported outcomes. Benefits were durable and continued post-treatment.

This led to FDA alignment for a Phase 3 trial (RESTORE) in chronic tetraplegia.

Evidence in StrokeStrong preclinical data: In a peer-reviewed mouse model of severe ischemic stroke (published in Cell Reports), the rodent analog (NVG-291-R / ISP) showed significant functional recovery in motor, sensory, and cognitive (memory) domains—even when started 7 days post-stroke. Effects included axonal sprouting, neuroblast migration into the lesion, reduced brain atrophy, and neuroprotection.

The company highlights preclinical efficacy in stroke (and other models like TBI, MS) as supporting broad potential.

No human clinical data yet for stroke—NVG-291 is primarily advancing in SCI, with NVG-300 (a next-gen candidate) in preclinical evaluation for stroke/ALS/etc.Why Effectiveness May Differ (Not "Just as Effective")Injury differences: SCI often involves a clear physical transection/compression with a dense scar at the injury site. Stroke is more diffuse (ischemic penumbra, varied locations in the brain), with additional issues like excitotoxicity, inflammation, and vascular damage. Recovery in stroke relies heavily on plasticity in surviving networks rather than long-distance regeneration.

Timing and lesion variability: SCI trials focused on chronic cases with incomplete injuries. Stroke timing (acute vs. chronic) and stroke type/location (e.g., cortical vs. subcortical) matter a lot.

Endpoints and magnitude: Hand function gains in tetraplegia are highly measurable and life-changing. Stroke recovery metrics (e.g., motor, cognition, speech) are broader and more heterogeneous—preclinical benefits were impressive but not identical in scope.

Biology isn't 1:1: While the core inhibitory pathway is shared, downstream effects and compensatory mechanisms differ between spinal cord and brain.

Overall OutlookThe shared mechanism gives good reason for optimism. Preclinical stroke data is encouraging (delayed treatment window is a big plus, as most stroke therapies are hyper-acute). If NVG-291 (or a follow-on) advances, stroke could be a logical expansion indication—similar to how the company positions it as a "neurorepair" platform.

That said, we won't know until human trials (Phase 2+ in stroke). Many therapies translate well preclinically but show smaller or context-specific effects in people.Bottom line: Not identical efficacy, but the science supports it being potentially transformative for stroke too, especially for promoting repair and plasticity in the subacute/chronic phase where options are limited. This is exciting progress in a field with huge unmet need. Keep an eye on NervGen's pipeline updates. Always consult specialists for personal medical advice.

https://biotechdistilled.substack.com/p/update-nervgen-pharma-ngen-a-50m

https://www.gurufocus.com/news/8956008/ngen-initiated-coverage-by-leerink-partners-rating-set-to-outperform

I'd focus on de-risking events. Large pharmaceutical companies usually pay substantially more once they believe the remaining risk is manageable.

For NervGen, these are the milestones I'd watch:

Milestone Buyout likelihood

Positive Phase 2 data Medium

FDA agreement on Phase 3 design Medium–High

Phase 3 enrollment underway High

Strong interim or pivotal Phase 3 data Very High

NDA/BLA filing or approval Very High

NervGen has already cleared several important hurdles:

Positive clinical data from CONNECT SCI.

FDA End-of-Phase 2 alignment.

Phase 3 (RESTORE) initiation planned and site activation underway.

Why a buyer might wait

A company like Johnson & Johnson, AbbVie, Roche, or Biogen could be interested in a therapy that genuinely restores neurological function. But they would probably want answers to questions such as:

Can the Phase 2 effect be reproduced in a registrational trial?

Is manufacturing scalable?

How large is the commercial opportunity beyond spinal cord injury?

Those answers significantly affect valuation.

Why Rogers could sell before approval

Adam Rogers has experience building companies toward value-creating exits. He doesn't necessarily need to wait for approval if an offer reflects a substantial portion of the expected future value.

There's another consideration: Phase 3 trials are expensive. Even after recent financings, NervGen has said its cash runway is limited and additional capital will likely be needed as the RESTORE trial progresses. A strategic partner or acquirer could eliminate financing risk.

My estimate

Based on the public information available today, I'd roughly frame the possibilities this way:

Acquired before Phase 3 starts: ~15–25%

Acquired during Phase 3 after strong execution or compelling additional data: ~40–50%

Acquired after successful Phase 3 or near approval: ~25–35%

Remains independent through commercialization: possible, but less likely if the clinical results continue to strengthen.

These aren't predictions—they're judgment calls based on how biotech acquisitions often unfold.

One thing that stands out to me is that management has been acting more like a company preparing for late-stage development than one preparing for an immediate sale. They've:

Added experienced regulatory and clinical executives.

Listed on Nasdaq.

Obtained FDA alignment for a registrational study.

Continued building the organization for Phase 3 execution.

Those steps increase the company's value whether it ultimately remains independent or is acquired. They don't rule out a buyout, but they don't suggest one is imminent either.

If NVG-291 ultimately demonstrates durable neurological recovery in a Phase 3 trial, it would be unusual not to attract serious acquisition interest from major pharmaceutical companies, given the scarcity of successful neuroregeneration therapies. The timing and price, however, would depend on how much remaining clinical and commercial risk a potential buyer believes still exists.

https://stocktwits.com/OldManLogan/message/657409580